beta2-adrenoreceptor
Could Repurposed Asthma Drugs Treat Parkinson’s Disease?
Posted on by Dr. Francis Collins

Thinkstock/ia_64
I had asthma as a child, and I still occasionally develop mild wheezing from exercising in cold air or catching a bad cold. I keep an inhaler on hand for those occasions, as this is a quick and effective way to deliver a medication that opens up those constricted airways. Now, an NIH-supported team has made the surprising discovery that some asthma medicines may also hold the potential to treat or help prevent Parkinson’s disease, a chronic, progressive movement disorder that affects at least a half-million Americans.
The results, published recently in the journal Science, provide yet another example of the tremendous potential of testing drugs originally intended for treating one disease for possible use in others [1]. In this particular instance, researchers screened a library of more than 1,100 well-characterized chemical compounds—including drugs approved by the Food and Drug Administration for treating asthma—to see if they showed any activity against a molecular mechanism known to be involved in Parkinson’s disease.
Share this:
- Click to share on LinkedIn (Opens in new window)
- Click to share on Pinterest (Opens in new window)
- Click to share on Tumblr (Opens in new window)
- Click to share on Reddit (Opens in new window)
- Click to share on Telegram (Opens in new window)
- Click to share on WhatsApp (Opens in new window)
- Click to print (Opens in new window)
Tags: a-syn, alpha-synuclein, approved drugs, asthma, beta blocker, beta2-adrenoreceptor, brain, clenbuterol, drug repurposing, drugs, genomics, inhaler, metaproterenol, motor system disorder, neurology, Norwegian Prescription Database, Parkinson's disease, Propranolol, repurposing drugs, salbutamol, SNCA gene